Crispr Therapeutics (NASDAQ:CRSP) stock is gaining on Tuesday after the Food and Drug Administration (FDA) granted exagamglogene autotemcel (exa-cel) a rolling review.
That rolling review starts in November and covers the use of exa-cel in treating sickle cell disease and transfusion-dependent beta thalassemia (TDT). This comes after the treatment was awarded several major regulatory designations.
Crispr Therapeutics submitted exa-cel in collaboration with Vertex Pharmaceuticals (NASDAQ:VRTX). The company expects to complete the application for review by the end of the first quarter of 2023.
Nia Tatsis Ph.D., executive vice president, chief regulatory and quality officer at Vertex Pharmaceuticals, said the following about the rolling review:
“We are pleased to have concluded our exa-cel pre-submission meetings with regulators and are excited that FDA has granted a rolling review. We continue to work with urgency to bring forward the first CRISPR therapy for a genetic disease, and one that holds potential to transform the lives of patients with sickle cell disease or beta thalassemia.”
Other Plans for Exa-cel
To go along with this, Vertex Pharmaceuticals has completed discussions with the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA). This has it expecting to submit that data by the end of the year.
CRSP stock is up 6.4% and CRTX stock is up 4.3% as of Tuesday morning.
Investors seeking out all of the latest stock market news are in luck!
We’ve got all of the hottest stock news traders need to know about for Tuesday! Among that is what stocks might soar after midterms, what renters need to know about the housing crash and more. You can get up to speed on all of that news at the following links!
More Tuesday Stock Market News
- Why Stocks Could Skyrocket Following the 2022 Midterm Elections
- Will a Housing Market Crash Be Good for U.S. Renters?
- Aquestive Therapeutics (AQST) Stock Gains on Positive Data for EpiPen Rival
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
